JP2021191802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021191802A5 JP2021191802A5 JP2021155526A JP2021155526A JP2021191802A5 JP 2021191802 A5 JP2021191802 A5 JP 2021191802A5 JP 2021155526 A JP2021155526 A JP 2021155526A JP 2021155526 A JP2021155526 A JP 2021155526A JP 2021191802 A5 JP2021191802 A5 JP 2021191802A5
- Authority
- JP
- Japan
- Prior art keywords
- product
- formulation
- weight
- chloride
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025014721A JP2025065198A (ja) | 2019-05-06 | 2025-01-31 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843819P | 2019-05-06 | 2019-05-06 | |
| US201962844069P | 2019-05-06 | 2019-05-06 | |
| US62/844,069 | 2019-05-06 | ||
| US62/843,819 | 2019-05-06 | ||
| US16/716,014 US10799481B1 (en) | 2019-05-06 | 2019-12-16 | Compositions and methods for treating ocular disorders |
| US16/715,998 | 2019-12-16 | ||
| US16/716,014 | 2019-12-16 | ||
| US16/715,998 US10814001B1 (en) | 2019-05-06 | 2019-12-16 | Oxymetazoline compositions |
| JP2020045468A JP7141420B2 (ja) | 2019-05-06 | 2020-03-16 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020045468A Division JP7141420B2 (ja) | 2019-05-06 | 2020-03-16 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014721A Division JP2025065198A (ja) | 2019-05-06 | 2025-01-31 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021191802A JP2021191802A (ja) | 2021-12-16 |
| JP2021191802A5 true JP2021191802A5 (enExample) | 2023-09-26 |
| JP7705326B2 JP7705326B2 (ja) | 2025-07-09 |
Family
ID=72750169
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020045468A Active JP7141420B2 (ja) | 2019-05-06 | 2020-03-16 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
| JP2021155526A Active JP7705326B2 (ja) | 2019-05-06 | 2021-09-24 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
| JP2025014721A Pending JP2025065198A (ja) | 2019-05-06 | 2025-01-31 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020045468A Active JP7141420B2 (ja) | 2019-05-06 | 2020-03-16 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014721A Pending JP2025065198A (ja) | 2019-05-06 | 2025-01-31 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (11) | US10814001B1 (enExample) |
| EP (1) | EP3965737A1 (enExample) |
| JP (3) | JP7141420B2 (enExample) |
| KR (3) | KR102410503B1 (enExample) |
| CN (2) | CN117045596A (enExample) |
| AU (1) | AU2020268329B2 (enExample) |
| BR (1) | BR112021022404A2 (enExample) |
| CA (1) | CA3139443A1 (enExample) |
| CL (1) | CL2021002918A1 (enExample) |
| CO (1) | CO2021015265A2 (enExample) |
| IL (1) | IL287831A (enExample) |
| MA (1) | MA55895A (enExample) |
| MX (1) | MX2021013516A (enExample) |
| PE (1) | PE20220384A1 (enExample) |
| SG (1) | SG11202112272TA (enExample) |
| WO (1) | WO2020227260A1 (enExample) |
| ZA (2) | ZA202108950B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| WO2022187306A1 (en) | 2021-03-03 | 2022-09-09 | Voom, Llc | Compositions and methods for treatment of blepharitis |
| WO2023079427A1 (en) * | 2021-11-03 | 2023-05-11 | Avaca Pharma Private Limited | Ophthalmic compositions and methods thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51421B1 (en) | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| JP2006131628A (ja) * | 2004-10-08 | 2006-05-25 | Rohto Pharmaceut Co Ltd | オキシメタゾリン含有水性組成物 |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US8466174B2 (en) | 2006-03-17 | 2013-06-18 | Johnson & Johnson Vision Care, Inc. | Methods for stabilizing oxidatively unstable compositions |
| WO2007127333A2 (en) | 2006-04-26 | 2007-11-08 | Aciex, Inc. | Compositions for the treatment and prevention of eyelid swelling |
| WO2008070185A2 (en) * | 2006-12-06 | 2008-06-12 | The Trustees Of Columbia University In The City Of New York | Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds |
| CN101951886A (zh) * | 2007-12-21 | 2011-01-19 | 先灵-普劳健康护理产品公司 | 增强羟甲唑啉的光稳定性 |
| SI2262506T1 (sl) * | 2008-03-11 | 2014-07-31 | Alcon Research, Ltd. | Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo |
| JP2012528888A (ja) * | 2009-06-05 | 2012-11-15 | アーシエックス セラピューティックス， インコーポレイテッド | 眼科用配合剤、その製造方法およびその使用方法 |
| US20120082625A1 (en) | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| EP2637684A4 (en) * | 2010-11-08 | 2014-05-07 | Healor Ltd | BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR |
| WO2012075319A2 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| CA2870158C (en) | 2012-05-25 | 2017-10-24 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
| UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| US10039220B2 (en) | 2013-09-18 | 2018-07-31 | Mycronic AB | Method, system and device for improved storage and handling of components |
| CA2951725C (en) | 2014-06-11 | 2022-06-07 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| US20170312335A1 (en) * | 2015-12-30 | 2017-11-02 | Lubris Llc | Topical use of prg4 for treatment of allergy and symptoms of inflammation |
| CN108883308A (zh) | 2016-01-26 | 2018-11-23 | 利维申制药有限公司 | α-肾上腺素能药剂的组合物和用途 |
| CN105997856A (zh) * | 2016-06-24 | 2016-10-12 | 魏威 | 盐酸羟甲唑啉滴眼液及其制备方法 |
| US11246816B2 (en) | 2016-06-30 | 2022-02-15 | The Procter And Gamble Company | Shampoo compositions comprising a chelant |
| US10814001B1 (en) * | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
-
2019
- 2019-12-16 US US16/715,998 patent/US10814001B1/en active Active
- 2019-12-16 US US16/716,014 patent/US10799481B1/en active Active
-
2020
- 2020-03-16 JP JP2020045468A patent/JP7141420B2/ja active Active
- 2020-04-01 CN CN202310901249.9A patent/CN117045596A/zh active Pending
- 2020-04-01 CN CN202010249167.7A patent/CN111888326B/zh active Active
- 2020-04-27 KR KR1020200050837A patent/KR102410503B1/ko active Active
- 2020-05-05 AU AU2020268329A patent/AU2020268329B2/en active Active
- 2020-05-05 PE PE2021001852A patent/PE20220384A1/es unknown
- 2020-05-05 EP EP20729894.4A patent/EP3965737A1/en active Pending
- 2020-05-05 CA CA3139443A patent/CA3139443A1/en active Pending
- 2020-05-05 MA MA055895A patent/MA55895A/fr unknown
- 2020-05-05 BR BR112021022404A patent/BR112021022404A2/pt unknown
- 2020-05-05 MX MX2021013516A patent/MX2021013516A/es unknown
- 2020-05-05 WO PCT/US2020/031425 patent/WO2020227260A1/en not_active Ceased
- 2020-05-05 SG SG11202112272TA patent/SG11202112272TA/en unknown
- 2020-10-05 US US17/063,416 patent/US10940138B2/en active Active
- 2020-10-07 US US17/064,915 patent/US10898573B1/en active Active
-
2021
- 2021-01-21 US US17/154,676 patent/US11103482B2/en active Active
- 2021-03-08 US US17/194,559 patent/US11324722B2/en active Active
- 2021-08-30 US US17/461,052 patent/US11311515B2/en active Active
- 2021-09-24 JP JP2021155526A patent/JP7705326B2/ja active Active
- 2021-11-04 IL IL287831A patent/IL287831A/en unknown
- 2021-11-05 CL CL2021002918A patent/CL2021002918A1/es unknown
- 2021-11-11 CO CONC2021/0015265A patent/CO2021015265A2/es unknown
- 2021-11-11 ZA ZA2021/08950A patent/ZA202108950B/en unknown
-
2022
- 2022-04-25 US US17/728,860 patent/US11541036B2/en active Active
- 2022-05-09 US US17/662,494 patent/US11701343B2/en active Active
- 2022-06-14 KR KR1020220072209A patent/KR102663319B1/ko active Active
- 2022-11-11 ZA ZA2022/12328A patent/ZA202212328B/en unknown
- 2022-12-23 US US18/146,127 patent/US20230355587A1/en active Pending
-
2023
- 2023-06-08 US US18/331,688 patent/US20240033250A1/en active Pending
-
2024
- 2024-04-29 KR KR1020240057166A patent/KR102859351B1/ko active Active
-
2025
- 2025-01-31 JP JP2025014721A patent/JP2025065198A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021191802A5 (enExample) | ||
| JP2018021007A5 (enExample) | ||
| JP2020007356A5 (enExample) | ||
| JP6886502B2 (ja) | アトロピン含有水性組成物 | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| JP2011513492A5 (enExample) | ||
| JP2013535472A5 (enExample) | ||
| JP2016534142A5 (enExample) | ||
| JP2005508981A5 (enExample) | ||
| JP2008540532A5 (enExample) | ||
| JP2010529999A5 (enExample) | ||
| JP2013501717A5 (enExample) | ||
| JP2019536761A5 (enExample) | ||
| JP2006516032A5 (enExample) | ||
| JP2011105739A5 (enExample) | ||
| CA2717605A1 (en) | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | |
| JP2016512210A5 (enExample) | ||
| JP2014515383A5 (enExample) | ||
| JP2019526591A5 (enExample) | ||
| JP2008523090A5 (enExample) | ||
| JP2019151627A5 (enExample) | ||
| RU2007117499A (ru) | Фармацевтические композиции, маскирующие вкус | |
| JP2007501817A5 (enExample) | ||
| CA2535533A1 (en) | Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline | |
| JP4757970B2 (ja) | 点眼剤組成物 |